Axogen

AXGN

Market cap $2.27B

AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance.

AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.

Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

ALACHUA, Fla. and TAMPA, Fla.

Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript

AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.

ALACHUA, Fla. and TAMPA, Fla.

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ALACHUA, Fla. and TAMPA, Fla.